Pixantrone: a novel aza-anthracenedione in the treatment of non-Hodgkin's lymphomas

Bibliography

• SWAIN SM, WHALEY FS, EWER MS: Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer (2003) 97(11):2869-2879.
   PubMed Web of Science ®Google Scholar
• DENNY WA, WAKELIN LP: Kinetics of the binding of mitoxantrone, ametantrone and analogues to DNA: relationship with binding mode and anti-tumour activity. Anticancer Drug Des. (1990) 5(2):189-200.
   PubMedGoogle Scholar
• CAVALLI F, JUNGI WF, NISSEN NI, PAJAK TF, COLEMAN M, HOLLAND JF: Phase II trial of cis-dichlorodiammineplatinum (II) in advanced malignant lymphoma: a study of the cancer and acute leukemia group B. Cancer (1981) 48(9):1927-1930.
   PubMed Web of Science ®Google Scholar
• CASASNOVAS RO, HAIOUN C, DUMONTET C et al.: Phase II study of 3-h infusion of high dose paclitaxel in refractory and relapsed aggressive non-Hodgkin's lymphomas. Groupe d'Etude des Lymphomes de l'Adulte. Haematologica (2000) 85(5):502-507.
   PubMed Web of Science ®Google Scholar
• FOSSA A, SANTORO A, HIDDEMANN W et al.: Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma. J. Clin. Oncol. (1999) 17(12):3786-3792.
   PubMed Web of Science ®Google Scholar
• O'REILLY SE, KLIMO P, CONNORS JM: The evolving role of etoposide in the management of lymphomas and Hodgkin's disease. Cancer (1991) 67(1 Suppl.):271-280.
   PubMed Web of Science ®Google Scholar
• PRESCOTT RJ, LEONARD RC: Pilot study and randomised trial of mitozantrone and ifosfamide for relapsed non-Hodgkin's lymphoma. Scotland and Newcastle lymphoma group (SNLG) working party on therapy. Leuk. Lymphoma (1993) 11(1-2):111-114.
   PubMed Web of Science ®Google Scholar
• PRESS OW, LEBLANC M, O'ROURKE TJ et al.: Phase II trial of paclitaxel by 24-h continuous infusion for relapsed non-Hodgkin's lymphomas: Southwest oncology group trial 9246. J. Clin. Oncol. (1998) 16(2):574-578.
   PubMed Web of Science ®Google Scholar
• TULPULE A, RARICK MU, KOLITZ J et al.: Liposomal daunorubicin in the treatment of relapsed or refractory non-Hodgkin's lymphoma. Ann. Oncol. (2001) 12(4):433-434.
   PubMed Web of Science ®Google Scholar
• PHILIP T, CHAUVIN F, BRON D et al.: PARMA international protocol: pilot study on 50 patients and preliminary analysis of the ongoing randomized study (62 patients). Ann. Oncol. (1991) 2(Suppl. 1):57-64.
   PubMed Web of Science ®Google Scholar
• JERKEMAN M, LEPPA S, KVALOY S, HOLTE H: ICE (ifosfamide, carboplatin, etoposide) as second-line chemotherapy in relapsed or primary progressive aggressive lymphoma-the Nordic lymphoma group experience. Eur. J. Haematol. (2004) 73(3):179-182.
   PubMed Web of Science ®Google Scholar
• REISER M, SCHNELL R, STRAUB G et al.: DIZE (dexamethasone, idarubicin, and continuous infusion of ifosfamide and etoposide): an effective and well-tolerated new regimen for patients with relapsed lymphoma. Leuk. Lymphoma (1998) 31(3-4):359-366.
   PubMed Web of Science ®Google Scholar
• MARTINO R, PEREA G, CABALLERO MD et al.: Cyclophosphamide, pegylated liposomal doxorubicin (Caelyx), vincristine and prednisone (CCOP) in elderly patients with diffuse large B-cell lymphoma: results from a prospective Phase II study. Haematologica (2002) 87(8):822-827.
   PubMed Web of Science ®Google Scholar
• BEGGIOLIN G, CRIPPA L, MENTA E et al.: BBR 2778, an aza-anthracenedione endowed with preclinical anticancer activity and lack of delayed cardiotoxicity. Tumori (2001) 87(6):407-416.
   PubMed Web of Science ®Google Scholar
• CAVALLETTI E, CRIPPA L, MAINARDI P et al.: Pixantrone (BBR 2778) has reduced cardiotoxic potential in mice pretreated with doxorubicin: comparative studies against doxorubicin and mitoxantrone. Invest. New Drugs (2007) 25(3):187-195.
   PubMed Web of Science ®Google Scholar
• FAIVRE S, RAYMOND E, BOIGE V et al.: A Phase I and pharmacokinetic study of the novel aza-anthracenedione compound BBR 2778 in patients with advanced solid malignancies. Clin. Cancer Res. (2001) 7:43-50.
   PubMed Web of Science ®Google Scholar
• BORCHMANN P, SCHNELL R, KNIPPERTZ R et al.: Phase I study of BBR 2778, a new aza-anthracenedione, in advanced or refractory non-Hodgkin's lymphoma. Ann. Oncol. (2001) 12:661-667.
   PubMed Web of Science ®Google Scholar
• DAWSON LK, JODRELL DI, BOWMAN A et al.: A clinical Phase I and pharmacokinetic study of BBR 2778, a novel anthracenedione analogue, administered intravenously, 3 weekly. Eur. J. Cancer (2000) 36(18):2353-2359.
   PubMed Web of Science ®Google Scholar
• CAVALETTI G, CAVALLETTI E, CRIPPA L et al.: Pixantrone (BBR 2778) reduces the severity of experimental allergic encephalomyelitis. J. Neuroimmunol. (2004) 151(1-2): 55-65.
   PubMed Web of Science ®Google Scholar
• BORCHMANN P, MORSCHHAUSER F, PARRY A et al.: Phase-II study of the new aza-anthracenedione, BBR 2778, in patients with relapsed aggressive non-Hodgkin's lymphomas. Haematologica (2003) 88:888-894.
   PubMed Web of Science ®Google Scholar
• BORCHMANN P, SCHNELL R, MORSCHHAUSER F et al.: A Phase I study of pixantrone (BBR 2778) in combination with cyclophosphamide, vincristine and prednisone in patients with relapsed aggressive non-Hodgkin's lymphoma. Blood (2003) 102:A642 (Abstract 2369).
   Google Scholar
• BORCHMANN P, HERBRECHT R, WILHELM M et al.: Results of a Phase II study of pixantrone in combination with cyclophosphamide, vincristine, and prednisone in patients with relapsed aggressive non-Hodgkin's lymphoma. ASH meeting 2006. Blood (2006) 108(11) (Abstract 529).
   Google Scholar
• LIM ST, FAYAD L, TULPULE A et al.: A Phase I/II trial of pixantrone (BBR 2778), methylprednisolone, cisplatin, and cytosine arabinoside (PSHAP) in relapsed/refractory aggressive non-Hodgkin's lymphoma. Leuk. Lymphoma (2007) 48(2):374-380.
   PubMed Web of Science ®Google Scholar
• SANTORO A, VOGLOVE J, GABRAIL N et al.: Comparative trial of pixantrone + rituximab versus single agent rituximab in the treatment of relapsed/refractory indolent non-Hodgkin's lymphoma (NHL). J. Clin. Oncol. ASCO Annual Meeting Proceedings Part I (2006) 24:S18 (Abstract 7578).
   Google Scholar
• FAYAD L, LIEBMANN J, MODIANO M et al.: Results of a Phase I/II trial of pixantrone in combination with fludarabine, dexamethasone, and rituximab in the treatment of patients with relapsed/refractory indolent non-Hodgkin's lymphoma (NHL). ASH meeting 2006. Blood (2006) 108(11) (Abstract 2758).
   Google Scholar